Terms: = Germ cell tumor AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
6103 results:
1. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
2. The involvement of RIPK4 in TNF-α-stimulated IL-6 and IL-8 production by melanoma cells.
Madej E; Lisek A; Brożyna AA; Cierniak A; Wronski N; Deptula M; Wardowska A; Wolnicka-Glubisz A
J Cancer Res Clin Oncol; 2024 Apr; 150(4):209. PubMed ID: 38656555
[TBL] [Abstract] [Full Text] [Related]
3. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
4. tumor-targeted therapy with braf-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract] [Full Text] [Related]
5. Genomic deletions explain the generation of alternative braf isoforms conferring resistance to MAPK inhibitors in melanoma.
Aya F; Lanuza-Gracia P; González-Pérez A; Bonnal S; Mancini E; López-Bigas N; Arance A; Valcárcel J
Cell Rep; 2024 Apr; 43(4):114048. PubMed ID: 38614086
[TBL] [Abstract] [Full Text] [Related]
6. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
[TBL] [Abstract] [Full Text] [Related]
7. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced braf-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
8. Efficiency and tolerance of second-line triple braf inhibitor/MEK inhibitor/anti-PD1 combined therapy in braf mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract] [Full Text] [Related]
9. Effective Targeting of Melanoma cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
10. braf V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
[No Abstract] [Full Text] [Related]
11. Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract] [Full Text] [Related]
12. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
13. RAF inhibitor re-challenge therapy in braf-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE; Roszik J; Ahmed J; Barretto CMN; Nardo M; Campbell E; Johnson AM; Piha-Paul SA; Oliva ICG; Weathers SP; Cabanillas M; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer; 2024 Mar; 23(1):64. PubMed ID: 38532456
[TBL] [Abstract] [Full Text] [Related]
14. Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care.
Fletcher KA; Johnson DB
Cancer J; 2024 Mar-Apr 01; 30(2):126-131. PubMed ID: 38527267
[TBL] [Abstract] [Full Text] [Related]
15. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract] [Full Text] [Related]
16. Metastatic Melanoma Treatment in Special Populations.
Miceli M; Boatwright C; Mehnert JM
Cancer J; 2024 Mar-Apr 01; 30(2):71-78. PubMed ID: 38527259
[TBL] [Abstract] [Full Text] [Related]
17. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract] [Full Text] [Related]
18. braf Mutated and Morphologically Spitzoid tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.
Gerami P; Chen A; Sharma N; Patel P; Hagstrom M; Kancherla P; Geraminejad T; Olivares S; Biswas A; Bosenberg M; Busam KJ; de La Fouchardière A; Duncan LM; Elder DE; Ko J; Landman G; Lazar AJ; Lowe L; Massi D; Mihic-Probst D; Parker DC; Scolyer RA; Shea CR; Zembowicz A; Yun SJ; Blokx WAM; Barnhill RL
Am J Surg Pathol; 2024 May; 48(5):538-545. PubMed ID: 38525831
[TBL] [Abstract] [Full Text] [Related]
19. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to braf inhibitors.
Muraro E; Montico B; Lum B; Colizzi F; Giurato G; Salvati A; Guerrieri R; Rizzo A; Comaro E; Canzonieri V; Anichini A; Del Vecchio M; Mortarini R; Milione M; Weisz A; Pizzichetta MA; Simpson F; Dolcetti R; Fratta E; Sigalotti L
Front Immunol; 2024; 15():1336566. PubMed ID: 38510242
[TBL] [Abstract] [Full Text] [Related]
20. The outcome in patients with braf-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract] [Full Text] [Related]
[Next]
